Why is Jagsonpal Pharma falling/rising?

As of 18-Sep, Jagsonpal Pharmaceuticals Ltd is currently priced at 244.30, reflecting an increase of 0.8, or 0.33%. Despite this slight uptick today, the stock has underperformed its sector by 0.72% and has experienced a decline of 1.65% over the past week and 2.04% over the past month. The stock has shown a trend reversal by gaining after two consecutive days of decline. While it is trading above its 20-day, 100-day, and 200-day moving averages, it remains below its 5-day and 50-day moving averages. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 14.92% against the 5-day average. However, the company has demonstrated strong long-term growth, with a 54.58% increase in profit after tax over the last six months and a healthy operating profit growth rate of 42.31%.
In the broader market context, the stock's recent performance contrasts with the benchmark Sensex, which has gained 1.80% over the past week and 2.14% over the past month. While Jagsonpal Pharmaceuticals has outperformed the BSE500 over the last year with a return of 50.90%, its short-term performance indicates a struggle to maintain momentum compared to the broader market. The company's low debt-to-equity ratio and consistent positive results over the last five quarters suggest a solid foundation for future growth, yet the recent decline in delivery volumes and underperformance relative to the sector may be contributing factors to its current price movement.